Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WILLOW long-term extension of enpatoran in lupus
2022-000239-21Phase 2Active
- Sponsor
- Merck KGaA
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of enpatoran in systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), subacute cutaneous lupus erythematosus (SCLE) and 1 more (2 arms), sponsored by Merck KGaA. Primary endpoint: Occurrence of adverse events. Started Jul 2022; status: active.
02
Drugs
enpatoran
03
Conditions
systemic lupus erythematosus (SLE)cutaneous lupus erythematosus (CLE)subacute cutaneous lupus erythematosus (SCLE)discoid lupus erythematosus (DLE)
Beyond the preview
Go deeper on 2022-000239-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000239-21.